Jasper Callemeyn1,2, Aleksandar Senev1,3, Maarten Coemans1, Evelyne Lerut4, Ben Sprangers2,5, Dirk Kuypers1,2, Alice Koenig6,7,8, Olivier Thaunat6,7,8, Marie-Paule Emonds3, Maarten Naesens9,2. 1. Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium. 2. Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium. 3. Histocompatibility and Immunogenetics Laboratory, Belgian Red Cross-Flanders, Mechelen, Belgium. 4. Department of Morphology and Molecular Pathology, University Hospitals Leuven, Leuven, Belgium. 5. Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology, KU Leuven, Leuven, Belgium. 6. International Center of Infectiology research (CIRI), French Institute of Health and Medical Research (INSERM) Unit 1111, Claude Bernard University Lyon I, National Center for Scientific Research (CNRS) Mixed University Unit (UMR) 5308, Ecole Normale Supérieure de Lyon, University of Lyon, Lyon, France. 7. Lyon-Est Medical Faculty, Claude Bernard University (Lyon 1), Lyon, France. 8. Department of Transplantation, Nephrology and Clinical Immunology, Edouard Herriot Hospital, Lyon, France. 9. Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, KU Leuven, Leuven, Belgium maarten.naesens@kuleuven.be.
Abstract
BACKGROUND: Circulating anti-HLA donor-specific antibodies (HLA-DSA) are often absent in kidney transplant recipients with microvascular inflammation (MVI). Missing self, the inability of donor endothelial cells to provide HLA I-mediated signals to inhibitory killer cell Ig-like receptors (KIRs) on recipient natural killer cells, can cause endothelial damage in vitro, and has been associated with HLA-DSA-negative MVI. However, missing self's clinical importance as a nonhumoral trigger of allograft rejection remains unclear. METHODS: In a population-based study of 924 consecutive kidney transplantations between March 2004 and February 2013, we performed high-resolution donor and recipient HLA typing and recipient KIR genotyping. Missing self was defined as the absence of A3/A11, Bw4, C1, or C2 donor genotype, with the presence of the corresponding educated recipient inhibitory KIR gene. RESULTS: We identified missing self in 399 of 924 transplantations. Co-occurrence of missing self types had an additive effect in increasing MVI risk, with a threshold at two concurrent types (hazard ratio [HR], 1.78; 95% confidence interval [95% CI], 1.26 to 2.53), independent of HLA-DSA (HR, 5.65; 95% CI, 4.01 to 7.96). Missing self and lesions of cellular rejection were not associated. No HLA-DSAs were detectable in 146 of 222 recipients with MVI; 28 of the 146 had at least two missing self types. Missing self associated with transplant glomerulopathy after MVI (HR, 2.51; 95% CI, 1.12 to 5.62), although allograft survival was better than with HLA-DSA-associated MVI. CONCLUSION: Missing self specifically and cumulatively increases MVI risk after kidney transplantation, independent of HLA-DSA. Systematic evaluation of missing self improves understanding of HLA-DSA-negative MVI and might be relevant for improved diagnostic classification and patient risk stratification.
BACKGROUND: Circulating anti-HLA donor-specific antibodies (HLA-DSA) are often absent in kidney transplant recipients with microvascular inflammation (MVI). Missing self, the inability of donor endothelial cells to provide HLA I-mediated signals to inhibitory killer cell Ig-like receptors (KIRs) on recipient natural killer cells, can cause endothelial damage in vitro, and has been associated with HLA-DSA-negative MVI. However, missing self's clinical importance as a nonhumoral trigger of allograft rejection remains unclear. METHODS: In a population-based study of 924 consecutive kidney transplantations between March 2004 and February 2013, we performed high-resolution donor and recipient HLA typing and recipient KIR genotyping. Missing self was defined as the absence of A3/A11, Bw4, C1, or C2 donor genotype, with the presence of the corresponding educated recipient inhibitory KIR gene. RESULTS: We identified missing self in 399 of 924 transplantations. Co-occurrence of missing self types had an additive effect in increasing MVI risk, with a threshold at two concurrent types (hazard ratio [HR], 1.78; 95% confidence interval [95% CI], 1.26 to 2.53), independent of HLA-DSA (HR, 5.65; 95% CI, 4.01 to 7.96). Missing self and lesions of cellular rejection were not associated. No HLA-DSAs were detectable in 146 of 222 recipients with MVI; 28 of the 146 had at least two missing self types. Missing self associated with transplant glomerulopathy after MVI (HR, 2.51; 95% CI, 1.12 to 5.62), although allograft survival was better than with HLA-DSA-associated MVI. CONCLUSION: Missing self specifically and cumulatively increases MVI risk after kidney transplantation, independent of HLA-DSA. Systematic evaluation of missing self improves understanding of HLA-DSA-negative MVI and might be relevant for improved diagnostic classification and patient risk stratification.
Authors: Bree Foley; Sarah Cooley; Michael R Verneris; Michelle Pitt; Julie Curtsinger; Xianghua Luo; Sandra Lopez-Vergès; Lewis L Lanier; Daniel Weisdorf; Jeffrey S Miller Journal: Blood Date: 2011-12-16 Impact factor: 22.113
Authors: Roman Reindl-Schwaighofer; Andreas Heinzel; Alexander Kainz; Jessica van Setten; Kira Jelencsics; Karin Hu; Bao-Li Loza; Michael Kammer; Georg Heinze; Petra Hruba; Alena Koňaříková; Ondrej Viklicky; Georg A Boehmig; Farsad Eskandary; Gottfried Fischer; Frans Claas; John C Tan; Tom J Albert; Jigar Patel; Brendan Keating; Rainer Oberbauer Journal: Lancet Date: 2019-02-14 Impact factor: 79.321
Authors: J van Bergen; A Thompson; G W Haasnoot; J I Roodnat; J W de Fijter; F H J Claas; F Koning; I I N Doxiadis Journal: Am J Transplant Date: 2011-06-30 Impact factor: 8.086
Authors: T H Tran; C Unterrainer; G Fiedler; B Döhler; S Scherer; A Ruhenstroth; M Adamek; D Middleton; G Opelz Journal: Am J Transplant Date: 2013-02-07 Impact factor: 8.086
Authors: Hannes Vietzen; Bernd Döhler; Thuong Hien Tran; Caner Süsal; Philip F Halloran; Farsad Eskandary; Carsten T Herz; Katharina A Mayer; Nicolas Kozakowski; Markus Wahrmann; Sarah Ely; Susanne Haindl; Elisabeth Puchhammer-Stöckl; Georg A Böhmig Journal: Front Immunol Date: 2022-03-24 Impact factor: 7.561
Authors: Katharina A Mayer; Klemens Budde; Philip F Halloran; Konstantin Doberer; Lionel Rostaing; Farsad Eskandary; Anna Christamentl; Markus Wahrmann; Heinz Regele; Sabine Schranz; Sarah Ely; Christa Firbas; Christian Schörgenhofer; Alexander Kainz; Alexandre Loupy; Stefan Härtle; Rainer Boxhammer; Bernd Jilma; Georg A Böhmig Journal: Trials Date: 2022-04-08 Impact factor: 2.279
Authors: Elisabet Van Loon; Baptiste Lamarthée; Thomas Barba; Sandra Claes; Maarten Coemans; Henriette de Loor; Marie-Paule Emonds; Priyanka Koshy; Dirk Kuypers; Paul Proost; Aleksandar Senev; Ben Sprangers; Claire Tinel; Olivier Thaunat; Amaryllis H Van Craenenbroeck; Dominique Schols; Maarten Naesens Journal: Front Immunol Date: 2022-02-23 Impact factor: 7.561
Authors: Philip F Halloran; Katelynn S Madill-Thomsen; Shane Pon; Majid L N Sikosana; Georg A Böhmig; Jonathan Bromberg; Gunilla Einecke; Farsad Eskandary; Gaurav Gupta; Luis G Hidalgo; Marek Myslak; Ondrej Viklicky; Agnieszka Perkowska-Ptasinska Journal: Am J Transplant Date: 2022-06-02 Impact factor: 9.369